Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV.
Fey T, Erickson N, Stahler A, Muenchhoff M, Keppler OT, Ruehlmann K, Krauss-Pfeiffer G, Steinberg H, Graf A, Krebs S, Blum H, Khatamzas E, Seynstahl S, Casuscelli J, Markwardt D, Forstpointner R, Schinköthe T, von Bergwelt-Baildon M, Heinemann V. Fey T, et al. Among authors: stahler a. Med Oncol. 2022 Apr 10;39(6):104. doi: 10.1007/s12032-022-01700-4. Med Oncol. 2022. PMID: 35397689 Free PMC article.
Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials.
Stahler A, Heinemann V, Ricard I, von Einem JC, Giessen-Jung C, Westphalen CB, Michl M, Heinrich K, Miller-Phillips L, Jelas I, Stintzing S, Modest DP. Stahler A, et al. J Cancer Res Clin Oncol. 2020 Aug;146(8):2077-2087. doi: 10.1007/s00432-020-03290-y. Epub 2020 Jun 19. J Cancer Res Clin Oncol. 2020. PMID: 32561975 Free PMC article. Review.
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Arends CM, Dimitriou S, Stahler A, Hablesreiter R, Strzelecka PM, Stein CM, Tilgner M, Saiki R, Ogawa S, Bullinger L, Modest DP, Stintzing S, Heinemann V, Damm F. Arends CM, et al. Among authors: stahler a. Blood. 2022 Mar 10;139(10):1593-1597. doi: 10.1182/blood.2021014108. Blood. 2022. PMID: 34932794 Free article. No abstract available.
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Kurreck A, Heinemann V, Fischer von Weikersthal L, Decker T, Kaiser F, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Graeven U, Heinrich K, Held S, Stahler A, Alig AHS, Jelas I, von Einem JC, Stintzing S, Giessen-Jung C, Modest DP. Kurreck A, et al. Among authors: stahler a. Front Oncol. 2022 Feb 18;12:751453. doi: 10.3389/fonc.2022.751453. eCollection 2022. Front Oncol. 2022. PMID: 35251955 Free PMC article.
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
Raschzok N, Stintzing S, Heinemann V, Rauch G, Ricke J, Guckenberger M, Kurreck A, Alig AHS, Stahler A, Bullinger L, Schmelzle M, Schöning W, Lurje G, Krenzien F, Haase O, Rau B, Gebauer B, Sauer IM, Pratschke J, Modest DP. Raschzok N, et al. Among authors: stahler a. BMC Cancer. 2022 Apr 2;22(1):359. doi: 10.1186/s12885-022-09422-6. BMC Cancer. 2022. PMID: 35366831 Free PMC article. Clinical Trial.
Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL.
Kumbrink J, Bohlmann L, Mamlouk S, Redmer T, Peilstöcker D, Li P, Lorenzen S, Algül H, Kasper S, Hempel D, Kaiser F, Michl M, Bartsch H, Neumann J, Klauschen F, von Bergwelt-Baildon M, Modest DP, Stahler A, Stintzing S, Jung A, Kirchner T, Schäfer R, Heinemann V, Holch JW. Kumbrink J, et al. Among authors: stahler a. Cancers (Basel). 2022 Jul 26;14(15):3631. doi: 10.3390/cancers14153631. Cancers (Basel). 2022. PMID: 35892888 Free PMC article.
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
Torlot L, Jarzab A, Albert J, Pók-Udvari Á, Stahler A, Holch JW, Gerlinger M, Heinemann V, Klauschen F, Kirchner T, Kumbrink J, Küster B, Jung A. Torlot L, et al. Among authors: stahler a. J Cancer Res Clin Oncol. 2023 Feb;149(2):669-682. doi: 10.1007/s00432-022-04416-0. Epub 2022 Nov 19. J Cancer Res Clin Oncol. 2023. PMID: 36401637 Free PMC article.
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Modest DP, et al. Among authors: stahler a. Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29. Ann Oncol. 2016. PMID: 27358379 Free PMC article.
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Modest DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Stahler A, Jung A, Kirchner T, Held S, Stintzing S, Giessen-Jung C, Heinemann V; XELAVIRI/AIO KRK0110 Investigators. Modest DP, et al. Among authors: stahler a. J Clin Oncol. 2019 Jan 1;37(1):22-32. doi: 10.1200/JCO.18.00052. Epub 2018 Nov 2. J Clin Oncol. 2019. PMID: 30388045 Clinical Trial.
50 results